Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience

SAKİN, Abdullah; yasar, nurgul; Sahin, Suleyman; ATCI, Muhammed Mustafa; GEREDELİ, Cağlayan; CİHAN, Sener; Arıcı, Serdar; DEMİR, Cumhur; ÜRÜN, Yonca YILMAZ

doi:10.14744/nci.2019.31384

Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience

Abdullah SAKİN, (Yüzüncü Yıl Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Van, Türkiye)

Yonca YILMAZ ÜRÜN, (Bülent Ecevit Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Zonguldak, Türkiye)

Süleyman ŞAHİN, (Van Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, Van, Türkiye)

Muhammed Mustafa ATCI, (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

Serdar ARICI, (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

Cağlayan GEREDELİ, (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

Nurgül YAŞAR, (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

Cumhur DEMİR, (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

Sener CİHAN (Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye)

İstanbul Kuzey Klinikleri

2 0

Yıl: 2020 Cilt: 7 Sayı: 3 Sayfa Aralığı: 267 - 274 Metin Dili: İngilizce DOI: 10.14744/nci.2019.31384 İndeks Tarihi: 18-09-2020

Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience

Öz:

OBJECTIVE: Squamous cell esophageal cancer (ESCC) is a highly fatal malignancy. This study aims to investigate the factorsaffecting survival in patients with metastatic and non-metastatic ESCC.METHODS: Between 2008 and 2016, 107 patients with ESCC who were followed up in an oncology clinic were included inthe analysis. Patients were grouped based on the stage of disease as clinical-stage II to IV.RESULTS: Of the 107 patients, 55 (55.1%) of them were male and 52 (48.6%) of them were female. The mean age was60.8 years. Based on the clinical-stage, 28 (26.2%) patients had stage II disease, 33 (30.8%) had stage III disease, and 46(43.0%) had stage IV disease. Twenty-nine (27.1%) patients with the non-metastatic disease underwent surgery followingneoadjuvant chemoradiotherapy (CRT), while 29 (27.1%) patients received definitive CRT. Twenty-six (56.5%) patients withmetastatic disease received chemotherapy (CT). While median overall survival (mOS) could not be reached in patients whounderwent surgery following neoadjuvant CRT, mOS for patients receiving definitive CRT versus patients treated with surgeryalone–was 22.0 months and 24.0 months, respectively (p=0.008). In the metastatic stage, mOS was 8.0 months for thepatients treated with a first-line CT and 3.0 months for patients receiving best supportive care (p<0.001). In multivariateanalysis, factors predicting survival in patients with the non-metastatic disease were ECOG PS 3-4 (Hazard ratio [HR], 6.13),undergoing surgery (HR, 0.22), clinical-stage III disease (HR, 3.19), and presence of recurrence (HR, 24.12). For patientswith metastatic disease, ECOG PS 3-4 (HR, 3.31), grade-III histology (HR, 3.39), liver metastasis (HR, 2.53), and receivingCT (HR, 0.15) were the factors associated with survival in multivariate analysis.CONCLUSION: In our study, surgery and early clinical-stage increased survival, whereas experiencing recurrence adverselyaffected survival in non-metastatic ESCC. In the metastatic stage, ECOG PS 3-4, grade-3 histology and liver metastasis adversely affected survival, while receiving CT significantly improved survival.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
2. Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol 2016;41:88–95.
3. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468–70.
4. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471–8.
5. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404–13.
6. Dandara C, Robertson B, Dzobo K, Moodley L, Parker MI. Patient and tumour characteristics as prognostic markers for oesophageal cancer: a retrospective analysis of a cohort of patients at Groote Schuur Hospital. Eur J Cardiothorac Surg 2016;49:629–34.
7. He Z, Zhao Y, Guo C, Liu Y, Sun M, Liu F, et al. Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey. Br J Cancer 2010;103:1085–8.
8. Randi G, Scotti L, Bosetti C, Talamini R, Negri E, Levi F, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer 2007;121:2049–51.
9. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84.
10. Suntharalingam M, Moughan J, Coia LR, Krasna MJ, Kachnic L, Haller DG, et al; 1996-1999 Patterns of Care Study. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys 2003;56:981–7.
11. Tsuchiya Y, Onda M, Miyashita M, Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol 1999;16:31–7.
12. Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, et al. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 2002;94:940–9.
13. Duan H, Zhang X, Wang FX, Cai MY, Ma GW, Yang H, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. World J Gastroenterol 2015;21:5591–7.
14. Sun P, Zhang F, Chen C, An X, Li YH, Wang FH, et al. Comparison of the prognostic values of various nutritional parameters in patients with esophageal squamous cell carcinoma from Southern China. J Thorac Dis 2013;5:484–91.
15. Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer. Eur J Surg Oncol 2015;41:1308–15.
16. Pottern LM, Morris LE, Blot WJ, Ziegler RG, Fraumeni JF Jr. Esophageal cancer among black men in Washington, D.C. I. Alcohol, tobacco, and other risk factors. J Natl Cancer Inst 1981;67:777–83.
17. Cavallin F, Scarpa M, Cagol M, Alfieri R, Ruol A, Sileni VC, et al. Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series. Ann Surg 2018;267:99–104.
18. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277–84.
19. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–7.
20. Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 2009;15:4962–8.
21. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274–9.
22. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–34.
23. Javle MM, Nwogu CE, Donohue KA, Iyer RV, Brady WE, Khemka SV, et al. Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus 2006;19:78–83.
24. Kumagai Y, Nagata K, Ishiguro T, Haga N, Kuwabara K, Sobajima J, et al. Clinicopathologic characteristics and clinical outcomes of esophageal basaloid squamous carcinoma: experience at a single institution. Int Surg 2013;98:450–4.
25. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78–86.
26. Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 2017;11:CD004063.

APA	SAKİN A, ÜRÜN Y, Sahin S, ATCI M, Arıcı S, GEREDELİ C, yasar n, DEMİR C, CİHAN S (2020). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. , 267 - 274. 10.14744/nci.2019.31384
Chicago	SAKİN Abdullah,ÜRÜN Yonca YILMAZ,Sahin Suleyman,ATCI Muhammed Mustafa,Arıcı Serdar,GEREDELİ Cağlayan,yasar nurgul,DEMİR Cumhur,CİHAN Sener Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. (2020): 267 - 274. 10.14744/nci.2019.31384
MLA	SAKİN Abdullah,ÜRÜN Yonca YILMAZ,Sahin Suleyman,ATCI Muhammed Mustafa,Arıcı Serdar,GEREDELİ Cağlayan,yasar nurgul,DEMİR Cumhur,CİHAN Sener Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. , 2020, ss.267 - 274. 10.14744/nci.2019.31384
AMA	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. . 2020; 267 - 274. 10.14744/nci.2019.31384
Vancouver	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. . 2020; 267 - 274. 10.14744/nci.2019.31384
IEEE	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S "Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience." , ss.267 - 274, 2020. 10.14744/nci.2019.31384
ISNAD	SAKİN, Abdullah vd. "Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience". (2020), 267-274. https://doi.org/10.14744/nci.2019.31384

APA	SAKİN A, ÜRÜN Y, Sahin S, ATCI M, Arıcı S, GEREDELİ C, yasar n, DEMİR C, CİHAN S (2020). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri, 7(3), 267 - 274. 10.14744/nci.2019.31384
Chicago	SAKİN Abdullah,ÜRÜN Yonca YILMAZ,Sahin Suleyman,ATCI Muhammed Mustafa,Arıcı Serdar,GEREDELİ Cağlayan,yasar nurgul,DEMİR Cumhur,CİHAN Sener Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri 7, no.3 (2020): 267 - 274. 10.14744/nci.2019.31384
MLA	SAKİN Abdullah,ÜRÜN Yonca YILMAZ,Sahin Suleyman,ATCI Muhammed Mustafa,Arıcı Serdar,GEREDELİ Cağlayan,yasar nurgul,DEMİR Cumhur,CİHAN Sener Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri, vol.7, no.3, 2020, ss.267 - 274. 10.14744/nci.2019.31384
AMA	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri. 2020; 7(3): 267 - 274. 10.14744/nci.2019.31384
Vancouver	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. İstanbul Kuzey Klinikleri. 2020; 7(3): 267 - 274. 10.14744/nci.2019.31384
IEEE	SAKİN A,ÜRÜN Y,Sahin S,ATCI M,Arıcı S,GEREDELİ C,yasar n,DEMİR C,CİHAN S "Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience." İstanbul Kuzey Klinikleri, 7, ss.267 - 274, 2020. 10.14744/nci.2019.31384
ISNAD	SAKİN, Abdullah vd. "Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience". İstanbul Kuzey Klinikleri 7/3 (2020), 267-274. https://doi.org/10.14744/nci.2019.31384